

FOR IMMEDIATE RELEASE

February 5, 2018

CONTACT: Pete Amstutz

(301) 983-2553

Pete@CreatvMicroTech.com

Creatv MicroTech at 2018 Mol Med Tri-CON - oral and poster presentations, exhibit and panel discussion

ROCKVILLE, MD - Creatv MicroTech (Creatv), a biotechnology company developing non-invasive cancer screening and diagnostics for all solid tumor, will be making an oral presentation on Monday, February 12, at 1:40 pm at Mol Med Tri-CON at San Francisco. Creatv will also participate on a panel discussion on commercialization of cancer diagnostics on Wednesday, February 14, at 3:40 pm.

Creatv developed CellSieve™ technology to capture all cancer associated cells in the blood of cancer patients. In the process of accurate identification of cells, Creatv discovered of a previously unpublished cell, very large polyploid cell, the cancer associated macrophage-like cell (CAML), in patient blood. CAMLs has enabled more informative and reliable blood based cancer diagnostics than circulating tumor cells (CTCs) and circulating tumor DNAs (ctDNA).

In the Tri-CON presentation, Creatv will focus on two clinical utilities. Creatv will show that CAMLs are found in all stages of major solid tumors, such as breast, prostate, lung, colon, esophageal, and others. CAMLs are found even in high percentages even in Stage 1. Thus, they are ideal for cancer screening. Creatv will also show that CAML properties provides very informative prognosis of the patient.

Creatv has also developed many other clinical applications based on a blood test: (1) companion diagnostics to determine therapy, (2) monitoring treatment response, (3) monitoring of tumor mutation, (4) determining residual disease, and (5) early detection of recurrence.

“We would like to thank all our collaborators,” said Cha-Mei Tang PhD, President and CEO of Creatv MicroTech. “They provide us not only patient samples, but also knowledge about cancer and the clinical applications that provide the most benefit to the patients.”

About Creatv MicroTech

-more-

Creatv MicroTech (www.creatvmicrotech.com) is a privately held company founded in 2000. Creatv has assembled expertise in biodetection and microfabrication, both of which were applied to develop the CellSieve™ microfiltration platform. Creatv has been recognized by an R&D 100 Award, inclusion on the Micro/Nano 25-Technologies of Tomorrow List, and Montgomery County Maryland's Bioscience Company of the Year Award.

CellSieve™ is a novel technology that enables the isolation and identification of CAMLs, as well as the better-known Circulating Tumor Cells. With data from over 2000 patient samples and 14 different solid tumors, CAMLs have consistently demonstrated utility in the early and reliable detection of cancer.

Creatv is now funded by National Cancer Institute of National Institute of Health, for double blinded study of 1000 patients for breast cancer screening and SBIR on effect of residual disease on lung cancer recurrence.

CellSieve™ assays are currently used in research and clinical trials in the US and eight other countries.